Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami ...

SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Germline testing identifies hereditary mutations ... The most well-known mutations are in the BRCA1 and BRCA2 genes, but others, such as TP53, PALB2, and ATM, are also implicated.

Germline BRCA2 pathogenic variants (PVs) are known to cause ~4% of prostate cancer, but other homologous repair genes, BRCA1, ATM, PALB2 and Lynch syndrome genes are also involved. Our objective was ...

05). Of those tested, 50 (17%) harbored a germline pathogenic or likely pathogenic variant. In the AMAZONA III trial, 1,476 (49%) of 2,974 patients with BC met the National Comprehensive Cancer ...

If you were recently diagnosed with breast cancer, you should ask your doctor to conduct germline or genetic testing. This test will look at all sorts of inherited mutations – including BRCA. This ...

We found that maternal rRNAs are not only expressed during oogenesis but are continuously produced in the zebrafish germline. Proteomic analyses of maternal and somatic ribosomes unveiled differences ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings. At a median follow-up of 41.2 months (IQR, 37 ...